Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PALB2 |
| Variant | S254Ifs*3 |
| Impact List | frameshift |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | PALB2 S254Ifs*3 indicates a shift in the reading frame starting at amino acid 254 and terminating 3 residues downstream causing a premature truncation of the 1186 amino acid Palb2 protein (UniProt.org). S254Ifs*3 has not been characterized, however, due to the effects of other truncation mutations downstream of S254 (PMID: 31757951, PMID: 31636395), is predicted to lead to a loss of Palb2 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
PALB2 mutant PALB2 inact mut PALB2 S254Ifs*3 |
| Transcript | NM_024675.4 |
| gDNA | chr16:g.23635787dupT |
| cDNA | c.759dupA |
| Protein | p.S254Ifs*3 |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001407302.1 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| NM_001407299.1 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| NM_001407301.1 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| XM_017023673.2 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| NM_001407298.1 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| NM_024675.3 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| NM_001407297.1 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| NM_001407300.1 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| XM_017023672.2 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| NM_024675.4 | chr16:g.23635787dupT | c.759dupA | p.S254Ifs*3 | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|